{"id":1244,"date":"2026-01-26T10:23:00","date_gmt":"2026-01-26T10:23:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/01\/26\/when-you-know-the-stereotyped-repopulation-you-get-what-you-get\/"},"modified":"2026-01-26T10:23:00","modified_gmt":"2026-01-26T10:23:00","slug":"when-you-know-the-stereotyped-repopulation-you-get-what-you-get","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/01\/26\/when-you-know-the-stereotyped-repopulation-you-get-what-you-get\/","title":{"rendered":"When you know the stereotyped repopulation\u2026.you get what you get"},"content":{"rendered":"
Tweet<\/a><\/div>\n

This study looks at what happens after cladribine, which is more of less the same as happens with alemtuzumab and HSCT but perhaps with different kinetics. when you deplete a B cell with anti-CD20 depleter, alemtuzumab and cladribine the circulating naive and memory cells disappear and the memory cells stay disappeared and the naive B cells get replaced by new immature and also naive B cells, so the variation of the remaining repopulation B cells expands….when you deplete T cells with alemtuzumab, HSCT and here cladribine the naive and Memory T cells get hit but the remaining mory T cells expand by a process calle homeostatic proliferation so a restricted T cell repertoire should emerge…In this study with cladridine you can read what they found and yep it is just as should be predicted. The memory B cell repertoire drops saying that some memory B cells disappear.<\/p>\n

In the paper they suggest that “our data 12\u2009months after completion of 2 cladribine cycles now indicate numerously reconstituting naive-like B cells in relapsing patients, which could suggest an association between a high potential for B-cell reconstitution \/\u2212differentiation and recurring disease activity.” This one view the other view would be not recurring disease but the potential to give vaccine responses<\/p>\n

EM, L\u00fcnemann JD, Wiendl H, Klotz L, Schwab N. Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment. Ann Neurol. 2026 Jan 23. doi: 10.1002\/ana.78165.\u00a0<\/p>\n

Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B- and T-cell receptor repertoires and relapse activity were assessed at baseline and after 24 months<\/strong>. T-cell clonality increased, driven by loss of low-frequency, naive clonotypes, and re-expansion of dominant CD8 memory clonotypes, particularly in clinically stable patients. In contrast, B-cell receptor richness increased because of reconstruction by transitional and naive B cells with higher clonotype numbers observed in relapsing patients. Therefore, competing immune reconstitution following cladribine therapy could result in differential clinical responses. ANN NEUROL 2026.<\/p>\n

Source: multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Tweet This study looks at what happens after cladribine, which is more of less the same as happens with alemtuzumab and HSCT but perhaps with different kinetics. when you deplete a B cell with anti-CD20 depleter, alemtuzumab and cladribine the circulating naive and memory cells disappear and the memory cells stay disappeared and the naive…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1244","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1244"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1244\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}